
VHL protein (β -domain : 1-154aa), His-tag, Human**Recombinant, *E.coli*****Cat. No. VHL3001****Size : 100 μ g**

Description: Von Hippel-Lindau disease(VHL) is a dominant inherited syndrome characterized by the predisposition to develop various kinds of benign and malignant tumors, including clear cell renal carcinomas, pheochromocytomas and hemangioblastomas of the central nervous system and retina. VHL syndrome is caused by germline mutation in the VHL tumor suppressor, and VHL tumors are associated with loss or mutation of the remaining wild-type allele.

VHL has two domains: a roughly 100-residue NH₂-terminal domain rich in β sheet(β -domain) and a smaller α -helical domain(α -domain), held together by two linkers and a polar interface. VHL protein is also involved in the degradation of hypoxia-inducible factor (HIF).

VHL β -domain(1-154aa) was overexpressed in *E.coli* and purified by using conventional chromatography techniques

Form : Liquid. In phosphate-buffered Saline(PBS), 2mM EDTA, pH7.4

Molecular weight : 19.2KDa (174amino acids)

Purity : \geq 95% by SDS-PAGE

Sequence : MGSSHHHHH SSGLVPRGSH MPRRAENWDE AEVGAEAGV EEYGPEEDGG EESGAEESGP
EESGPEELGA EEEMEAGRPR PVLRSVNSRE PSQVIFCNRS PRVVLVWLN FDGEPQPYPT
LPPGTGRRIH SYRGHLWLFK DAGTHDGLLV NQTELFVPSL NVDGQPIFAN ITLP

Storage : Store at -20°C. Avoid freeze/thaw cycles.

References :

- Latif, F., *et al* (1993) *Science*. 260(5112),1317-1320
- Duan,D.R., *et al*(1995) *Proc.Natl.Acad.Sci. U.S.A.* 92(14),6459-6463
- Maxwell,P.H., *et al* (1999) *Nature* 399(6733), 271-275
- Chales E. Stebbins, *et al*(1999) *Science* 284, 455-461
- Staller, P. *et al* (2003) *Nature* 425, 307-311

